| FORMULATION |
|
| Our speciality product range features solid oral dosage forms (tablets, capsules), injections, nasal sprays, aerosols, dry powder inhalers, ophthalmic preparations, creams and ointments as well as technically complex preparations like melt tabs, liposome based products, depot preparations and time release / controlled release preparations. |
|
Currently tableting capacity across all our plants is in excess of 10000 mill tabs/yr.
The plant at Halol is spread over 65,000 sq. mt. and holds USFDA approval as well as UKMHRA approval. It has manufacturing lines for a large number of dosage forms (sterile dry powder injections, small volume injections, tablets, capsules, aerosols, liposomal and depot preparations, ointments). A new injectable plant with 7 manufacturing lines, spread over 36,000 sq. ft has recently been added. Of particular interest is an oral solid dosage form area that is USFDA approved, and a large injectable and nasal spray area that recently received USFDA approval. These areas are used for our filings for the US generic market.
This plant recently received approvals from the South African MCC, the Columbian regulatory agency INVIMA and the Brazilian agency ANVISA. |
|
| A state-of-the-art formulation plant in Dhaka makes formulations for this important market. Our internationally approved plant in India, and our increasing US presence with recently acquired plants in New Jersey and Ohio take our manufacturing skills to a global platform. |
|
| The factories at Dadra, Jammu and Silvassa are equipped to manufacture solid oral finished dosages to international regulatory requirements. These facilities comply with cGMP, WHO standards and are approved by local FDA with excellent regulatory compliance records. Currently these plants meet requirements for the market in India, as well as select international markets. For instance, the Silvassa plant is approved for a number of markets including Tanzania and Peru. |
|
| Click here to view a list of our Formulation Plants. |
|
|
|
|
|
|
 |
|
|
|
|
|
|
|
News Articles
Contact Us
